Heart Failure - DAPA TIMI 68

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure

Dr. Jaiswal and Hartford Hospital’s Heart Failure Department are enrolling patients in this international trial for patients with heart failure and reduced ejection fraction who will be randomized to dapagliflozin versus placebo while in the hospital. 

Eligibility Criteria:

  • Currently hospitalized for acute heart failure including volume overload treated with intravenous medication

Please contact Khadija El Aoudi at 860-972-3167 or by email at Khadija.elaoudi@hhchealth.org for more information.